Skip to main content
Equibles
FTRE logo

FTRE · Fortrea Holdings Inc.

Track FTRE — free

Use FTRE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about FTRE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$17.41 -0.41 (-2.30%) At close · Aug 14
Market Cap
$1.66B
Shares
95.10M

Fortrea Holdings Inc. Earnings Call Transcripts

Every quarterly earnings call for Fortrea Holdings Inc. (FTRE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼8.6% $725.10M $30.80M '23 Q2 23-08-14 ▼6.4% $713.80M −$14.00M '23 Q3 23-11-13 · $709.70M −$54.50M '23 Q4 24-03-11 ▼4.6% $662.10M −$101.00M '24 Q1 24-05-13 ▼8.6% $662.40M −$138.40M '24 Q2 24-08-12 ▼5.4% $674.90M −$27.90M '24 Q3 24-11-08 ▼1.8% $697.00M −$61.20M '24 Q4 25-03-03 ▼1.6% $651.30M −$562.90M '25 Q1 25-05-12 ▲7.2% $710.30M −$374.90M '25 Q2 25-08-06 ▲3.9% $701.30M −$15.90M '25 Q3 25-11-05 ▼5.2% $660.50M −$32.50M '25 Q4 26-02-26 ▼2.3% $636.50M −$23.60M '26 Q1 26-05-05 LATEST ▼4.5% $678.20M −$13.20M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
Fortrea Q2'26 Earnings Conference Call
Positive tone Guidance raise / financial performance Commercial excellence and book-to-bill Therapeutic and geographic mix
Revenue
$678.20M
▼ 4.5% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Fortrea Holdings Inc. Q1 FY2026 Earnings Call
Positive tone Biotech demand recovery Guidance and revenue conversion timing Fortrea Intelligent Technology (FIT) launch
Revenue
$636.50M
▼ 2.3% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Fortrea Holdings Inc. Q4 FY2025 Earnings Call
Positive tone Clinical pharmacology and FSP dynamics Bookings and demand recovery Commercial framework (3Rs)
Revenue
$660.50M*
▼ 5.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Fortrea Holdings Inc. Q3 FY2025 Earnings Call
Positive tone FSP business and pricing discipline Backlog and book-to-bill Clinical pharmacology and new awards
Revenue
$701.30M
▲ 3.9% YoY
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Fortrea Holdings Inc. Q2 FY2025 Earnings Call
Balanced tone Margin optimization and cost initiatives Guidance update Bookings and book-to-bill weakness
Revenue
$710.30M
▲ 7.2% YoY
Diluted EPS
$-4.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Fortrea Holdings Inc. Q1 FY2025 Earnings Call
Positive tone Bookings and pipeline SG&A cost reduction Gross margin and project ramp
Revenue
$651.30M
▼ 1.6% YoY
Diluted EPS
$-6.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Fortrea Holdings Inc. Q4 FY2024 Earnings Call
Cautious tone Pre-spin vs post-spin project economics Book-to-bill and backlog growth Clinical Pharmacology Services (CPS)
Revenue
$697.00M*
▼ 1.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Fortrea Holdings Inc. Q3 FY2024 Earnings Call
Positive tone Biotech and Large Pharma Mix Bookings and Book-to-Bill Clinical Pharmacology (CPS/Phase 1)
Revenue
$674.90M
▼ 5.4% YoY
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Fortrea Holdings Inc. Q2 FY2024 Earnings Call
Positive tone Biotech contracting unpredictability Large pharma wins and pipeline Book-to-bill and bookings shortfall
Revenue
$662.40M
▼ 8.6% YoY
Diluted EPS
$-1.55
▼ 542.9% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Fortrea Holdings Inc. Q1 FY2024 Earnings Call
Balanced tone Demand and Book-to-Bill Commercial Transformation and Customer Mix Capital Structure
Revenue
$662.10M
▼ 4.6% YoY
Diluted EPS
$-1.13
▼ 907.1% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-11
Fortrea Holdings Inc. Q4 FY2023 Earnings Call
Positive tone Bookings and commercial momentum Spin-off completion and operating as standalone Brand and demand generation
Revenue
$709.70M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Fortrea Holdings Inc. Q3 FY2023 Earnings Call
Revenue
$713.80M
▼ 6.4% YoY
Diluted EPS
$-0.16
▼ 123.5% YoY
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Fortrea Holdings Inc. Q2 FY2023 Earnings Call
Revenue
$725.10M
▼ 8.6% YoY
Diluted EPS
$0.35
▼ 53.3% YoY
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–14 of 14 earnings calls
Key facts CIK 1965040 CUSIP 34965K107 13F (30d) 317 filings 304 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)